Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Natural Killer Cell (CYNK-001) Infusions in Adults with AML [Phase 1]
Phase 1 trial examining CYNK-001 natural killer cell infusions in adults with acute myeloid leukemia; the study was terminated.
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: T-cell Receptor α/β Depleted Donor Lymphocyte Infusion [Phase 1]
Phase 1 trial of T-cell receptor α/β-depleted donor lymphocyte infusion was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy [Phase 2]
A Phase 2 clinical trial evaluating venetoclax in combination with five days of azacitidine in untreated acute myeloid leukemia patients who…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: A Study of TAS1440 With ATRA in Subjects With r/r AML [Phase 1]
A Phase 1 study of TAS1440 in combination with all-trans retinoic acid for relapsed or refractory acute myeloid leukemia has been terminated…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) [Phase 2]
Phase 2 clinical trial update of flotetuzumab for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell tr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]
Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…
-
CLINICAL_TRIALS withdrawal · 2024-12-05Clinical Trial Update: Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT [Phase 1]
A Phase 1 trial evaluating a preemptive infusion of donor lymphocytes depleted of TCR+ T cells and CD19+ B cells after autologous stem cell …
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
A clinical trial is evaluating the PET imaging tracer 68Ga-DOTA-Siglec-9 in cancer patients. The study is currently enrolling by invitation …
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Vyxeos for Induction of Low- or Intermediate-risk. [Phase 2]
This update reports on a Phase 2 study of Vyxeos (CPX-351) as induction therapy for adults with acute myeloid leukemia at low- or intermedia…
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML [Phase 2]
This update describes a Phase 2 trial comparing venetoclax plus azacitidine against intensive chemotherapy in fit patients with newly diagno…
-
CLINICAL_TRIALS trial_result · 2024-11-29Clinical Trial Update: Assessing Refractoriness and Infectious Survival Events in AML
A completed AML clinical trial update focusing on refractoriness and infectious survival events.
-
CLINICAL_TRIALS trial_result · 2024-11-27Clinical Trial Update: A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) [Phase 1]
Phase 1 trial of evorpacept (ALX148) in combination with venetoclax and azacitidine for adults with acute myeloid leukemia has been terminat…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia [EARLY_Phase 1]
Early-phase clinical trial evaluating induced pluripotent stem cell-derived natural killer cells for refractory or relapsed acute myeloid le…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) [EARLY_Phase 1]
This early-phase (Phase 1) clinical trial update reports completion of a study evaluating CD7-targeted CAR-T cell therapy in patients with r…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia [Phase 1]
This is a Phase 1 clinical trial evaluating CD70-CAR-NK cell therapy for relapsed/refractory T-cell lymphoma and relapsed/refractory acute m…
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) [Phase 2]
Phase 2 trial evaluating the WT1 vaccine in patients in remission from acute myeloid leukemia or acute lymphoblastic leukemia has completed …
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers [Phase 1, Phase 2]
Clinical trial update for Galinpepimut-S in combination with pembrolizumab in selected advanced cancers (Phase 1/2) with completed status an…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating single-agent and combined inhibition after allogeneic stem cell transplant in patients with acute myeloid …
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies [Phase 1]
Phase 1 study of VIP943 in adults with advanced CD123+ hematologic malignancies is currently recruiting, including acute myeloid leukemia, B…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN [Phase 1]
Phase 1 clinical trial evaluating a CD123-targeted CAR-NK cell therapy for relapsed/refractory acute myeloid leukemia or blastic plasmacytoi…
-
CLINICAL_TRIALS withdrawal · 2024-11-14Clinical Trial Update: Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
The Phase 1 safety and efficacy study of CI-135 CAR-T cells for relapsed or refractory acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy [NA]
A clinical trial update evaluating venetoclax in combination with intensive therapy for acute myeloid leukemia patients who show low early p…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating atorvastatin for mitigating cardiotoxicity in acute myeloid leukemia; the study is not yet recruiting…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating sequential CAR-T cells targeting CD33 and CD123 in adults with acute myeloid leukemia is current…